No Data
US Stock MarketDetailed Quotes
XSNX NOVACCESS GLOBAL INC
Watchlist
0.027500
+0.000750+2.80% Close 12/06 16:00 ET
0.030000High0.023000Low43.72KVolume
0.023500Open0.026750Pre Close1.22KTurnover0.37%Turnover RatioLossP/E (TTM)592.23KMarket Cap0.29000052wk HighLossP/E (Static)21.54MShares0.02300052wk Low-0.10P/B329.33KFloat Cap0.970000Historical High--Dividend TTM11.98MShs Float0.023000Historical Low--Div YieldTTM26.17%Amplitude0.027000Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About NOVACCESS GLOBAL INC Company
NovAccess Global, Inc. is a biopharmaceutical company, which engages in the provision of diagnostics, therapeutics in cancer, and neurological diseases and the development of immunotherapies to treat brain tumor patients. The company was founded on February 25, 1997 and is headquartered in Cuyahoga County, OH.
Revenue Breakdown
Business
Currency:USD
2019/09/30
Stock NameRevenueRatio
Single segment1.61M100.00%
News
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit.Event:December 7th In
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the app
NovAccess Global Partners With BCN Biosciences to Expand Immunotherapy Platform
Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS TumorsPotential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology MarketCLEVELAND, OH /